The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,471,214 in first-year total cost, median $392,663.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-A (11)]3
- Special Emphasis Panel[ZRG1 RPHB-Y (12)]2
Most frequent institutions
- BIOSENSICS, LLC1
- COGNITION THERAPEUTICS, INC.1
- HEALTHY DESIGN, LTD. CO.1
- STARWISE THERAPEUTICS, LLC1
- SYNAPTEX, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction2R42AG052249-02A1 | IZZO, NICHOLAS JOHN | COGNITION THERAPEUTICS, INC., PA | $1,054,468 | ZRG1 |
| 2018 | A novel wearable platform to assess cognitive-motor performance1R41AG058295-01A1 | NAJAFI, BIJAN | BIOSENSICS, LLC, MA | $402,769 | ZRG1 |
| 2018 | Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment1R42AG059451-01 | NEEDHAM, DALE MURRAYSTAPLETON, RENEE D | HEALTHY DESIGN, LTD. CO., VT | $371,807 | ZRG1 |
| 2018 | Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.1R41AG060836-01 | REDDY, P. HEMACHANDRA | SYNAPTEX, LLC, TX | $249,507 | ZRG1 |
| 2017 | Study of the New HDAC6i SW-100 as a Treatment for Alzheimer’s Disease and Other Tauopathies1R41AG058283-01 | GORDON, MARCIA NKOZIKOWSKI, ALAN P.MORGAN, DAVID | STARWISE THERAPEUTICS, LLC, IL | $392,663 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.